Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-12-03
2002-04-09
Nguyen, Dave T. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C424S093200, C604S058000, C604S058000, C604S058000
Reexamination Certificate
active
06369039
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the site-specific delivery of therapeutic agents to target locations within body cavities, vasculatures, or tissues.
BACKGROUND
The treatment of disease such as vascular disease by local pharmacotherapy presents a means of delivering therapeutic drug doses to target tissues while minimizing systemic side effects. Recently, for example, the local delivery of gene constructs to effect vascular response has gained increased interest. Gene transfection of vascular smooth muscle cells in vivo, however, remains a problem due to low transfer efficiency attributed in part to inefficient local delivery devices and to the barrier properties of the vessel wall.
As an example of localized delivery of therapeutic agents, in vivo adenoviral gene transfer has been accomplished with the use of site-specific delivery catheters. Independent of the local delivery device used, most studies have delivered viral doses ranging from 1×10
9
to 1×10
10
pfu/ml over extended delivery times of 20 minutes or longer, and typically in delivery volumes of 1 ml or more. Although these conditions are widely used, the lack of optimization studies with local delivery devices suggests that delivery conditions are not necessarily optimal. Moreover, conventional localized techniques are often invasive in that they typically involve side branch ligation, long delivery times, and when the delivery device is an expandable device such as a balloon catheter, these techniques usually are associated with high pressures to accomplish drug delivery. Localized delivery techniques making use of long delivery times and high pressures and volumes often result in tissue damage, ischemia and other problems. Attempts have been made to reduce the delivery time from an infusion based device using a polymer carrier such as Poloxamer (BASF Corporation), whereby delivery times are reduced from 30 minutes to 5 minutes. The clinical utility of this approach, however, remains uncertain.
SUMMARY OF THE INVENTION
In one aspect, the present invention includes a method of site-specifically delivering a therapeutic agent to a target location within a body cavity, vasculature or tissue. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the medical device into the body cavity, vasculature or tissue; releasing a volume of the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres for a time of up to about 5 minutes; and withdrawing the medical device from the body cavity, vasculature or tissue.
In another aspect, the present invention includes a system for delivering a therapeutic agent to a body cavity, vasculature or tissue, comprising a medical device having a substantially saturated solution of the therapeutic agent associated therewith.
REFERENCES:
patent: 4487808 (1984-12-01), Lambert
patent: 5041107 (1991-08-01), Heil, Jr.
patent: 5061237 (1991-10-01), Gessler et al.
patent: 5102402 (1992-04-01), Dror et al.
patent: 5103817 (1992-04-01), Reisdorf et al.
patent: 5380299 (1995-01-01), Fearnot et al.
patent: 5383928 (1995-01-01), Scott et al.
patent: 5464395 (1995-11-01), Faxon et al.
patent: 5599294 (1997-02-01), Edwards et al.
patent: 5624411 (1997-04-01), Tuch
patent: 5652225 (1997-07-01), Isner
patent: 5674192 (1997-10-01), Sahatjian et al.
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5763416 (1998-06-01), Bonadio
patent: 5800525 (1998-09-01), Bachinski et al.
patent: 5846225 (1998-12-01), Rosengart et al.
patent: 5981568 (1999-11-01), Kunz
patent: 6228845 (2001-05-01), Donovan et al.
patent: 6251886 (2001-06-01), Friedman
patent: 6273913 (2001-08-01), Wright et al.
patent: 0 372 088 (1989-02-01), None
patent: 0 364 787 (1990-04-01), None
patent: 2 127 839 (1983-09-01), None
patent: 2 153 235 (1985-08-01), None
patent: WO92/11896 (1992-07-01), None
patent: WO97/41916 (1997-11-01), None
patent: WO98/35784 (1998-08-01), None
Anderson et al., Nature, vol. 392, 25-30, 1998.*
Verma et al. (Nature, vol. 389, 18, pp. 239-242, 1997.*
Branch (TIBS 23, pp. 45-50), 1998.*
Alain Tedgui and M. John Lever, American Journal of Physiology, Effect of pressure and intimal damage on131I-albumin and [14C] sucrose spaces in aorta,Dec. 1987, vol. 253/No. 6, 1530-1539.
Tahlil, Ouafae et al.,Cardiovascular Research, The Dispatch catheter as a delivery tool for arterial gene transfer,Jan. 1997, vol. 33, No. 1,181-187.
Schulick, Andrew H., MD, et al.,Circulation, In Vivo Gene Transfer Into Injured Carotid Arteries, vol. 91, No. 9, May 1, 1995,2407-2414.
Feldman, Laurent J. et al. Cardiovascular Research, Optimal techniques for arterial gene transfer, 1997, Research 35, 391-404.
Vassalli, Giuseppe and Dichek, David A., Cardiovascular Research, Gene therapy for arterial thrombosis, 1997, Research 35, 459-469.
Gerard, Robert D. and Collen, Desire, Cardiovascular Research, Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis, 1997, Research 35, 451-458.
Steg, P. Gavriel, MD, et al.,Circulation, Arterial Gene Transfer to Rabbit Endothelial and Smooth Muscle Cells Using Percutaneous Delivery of an Adenoviral Vector, Oct. 1994, Vol. 90, No. 4,1648-1656.
Willard, John E., MD, et al., Circulation, Genetic Modification of Vessel Wall, May 1994, vol. 89, No. 5, 2190-2197.
Ohno, Taskeshi, et al., Science, Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury, Aug. 1994, vol. 265, 781-784.
Asahara, Takayuki, MD, et al., Circulation, Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery, Jun. 1, 1995, vol. 91, No. 11, 2793-2801.
Tedgui, Alain and Lever, M. John, Circulation Research, The Interaction of Convection and Diffusion in the Transport of131I-Albumin within the Media of the Rabbit Thoracic Aorta, Dec. 1985, vol. 57, No. 6, 856-863.
Moura, Alvaro, MD, et al., Circulation, Intramural Delivery of Agent via a Novel Drug-Delivery Sleeve, Oct. 15, 1995, vol. 92, No. 8, 2299-2305.
Lewis, Basil S., et al., Cardiovascular Research, Angiogenesis by gene therapy: a new horizon for myocardial revascularization?, Sep. 1997, vol. 35, No. 3, 490-497.
Swain, Judith L., MD, Circulation, GENE THERAPY A New Approach to the Treatment of Cardiovascular Disease, Nov. 1989, vol. 80, No. 5, 1495-1496.
American Heart Association, Supplemental to Circulation, Oct. 15, 1995, vol. 92, No. 8, 670-672.
Axel, Dorothea I., et al., Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo and In Vivo Using Local Drug Delivery, Jul. 15, 1997,636-651.
Gehrke, S.H., et al., “Enhanced loading and activity retention of bioactive proteins in hydrogel delivery systems,” Journal of Controlled Release 55 (1998) pp. 21-33.
Palasis Maria
Walsh Kenneth
Kenyon & Kenyon
Nguyen Dave T.
Scimed Life Sytems, Inc.
LandOfFree
High efficiency local drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High efficiency local drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High efficiency local drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2887076